Celltrion Promotes the Excellence of Jimpendra at the World's Largest Gastroenterology Conference

Celltrion announced on the 20th that it participated in the '2024 Digestive Disease Week (DDW)' held in Washington DC, USA from the 18th to the 21st (local time), and revealed positive clinical results of Jimpendra, the world's only subcutaneous infliximab formulation for autoimmune disease treatment.

Overview of the Celltrion booth set up at the 2024 Digestive Disease Week (DDW) in the United States
[Photo by Celltrion]

DDW is the world's largest academic conference where global experts with significant influence in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery gather. This year, over 13,000 medical professionals from various countries are attending to share and communicate the latest medical trends related to inflammatory bowel disease (IBD) and more.

This DDW participation marks Celltrion's first major conference attendance since the U.S. launch of Jimpendra in March. Through this participation, the company is continuing various activities to enhance product and corporate awareness among local medical professionals and key stakeholders.

First, on the 19th, Celltrion disclosed the two-year (102-week) long-term follow-up results of the global Phase 3 clinical trial for Jimpendra’s new drug approval, conducted on 180 Crohn's disease patients and 237 ulcerative colitis patients. These results were first revealed at the European Crohn's and Colitis Organisation (ECCO) meeting held in February, receiving high praise from local medical professionals. This was the first time the data was disclosed in the U.S. at DDW.

This study extended treatment up to 102 weeks for patients who had undergone maintenance therapy with Jimpendra for 54 weeks (1 year), observing long-term efficacy and safety. The clinical results showed efficacy at 102 weeks similar to that at 54 weeks, and no new safety concerns were identified. Given the positive research outcomes regarding treatment efficacy and safety, it is expected that the burden on U.S. physicians prescribing Jimpendra will be alleviated, leading to increased prescription preference.

Celltrion is also conducting various marketing activities targeting medical professionals attending DDW. On the 20th, a seminar titled ‘Achieving Long-term Treatment Goals with Jimpendra - Endoscopic Treatment and Mucosal Healing’ was held at the Celltrion booth, introducing Jimpendra data analysis results based on the latest trends in IBD treatment. Following this, on the 21st, a symposium titled ‘Understanding Jimpendra - The World’s First and Only Subcutaneous Infliximab Formulation Offering New Treatment Options for Maintenance Therapy in Ulcerative Colitis and Crohn’s Disease’ will be held to actively promote Jimpendra’s treatment efficacy and product competitiveness.

Celltrion's autoimmune disease treatment drug, Jimptetra [Photo by Celltrion]

A Celltrion representative stated, "Research data proving the efficacy and safety of Jimpendra continue to be disclosed at globally renowned academic conferences, attracting great interest and positive responses from global scholars," adding, "As achievements expand, including recent listing as a preferred drug on the formularies of major U.S. pharmacy benefit managers (PBMs), activities to inform medical professionals about the product’s competitiveness and increase preference will further accelerate Jimpendra’s prescription momentum."